Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Beth O. Van Emburgh(Valve (United States)), Alberto Bardelli(IFOM)
Cited by 211
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770